OBJECTIVE: The purpose of this study was to evaluate the safety of intravitreal ocriplasmin prospectively, reporting potential complications in @entity1 with vitreomacular traction (VMT) alone or associated with @entity937 ( @entity937 ). MATERIALS AND METHODS: @entity1 in this prospective, multicenter study, were 24 @entity1 with VMT (17 with VMT alone and seven with @entity937 combined with VMT). All @entity1 were treated with a single ocriplasmin injection and followed-up prospectively at baseline, day 7, 28 and the last examination of the follow-up for each @entity1 (mean        SD: 64.2        24.4 d, range: 40-145 d). Best-corrected visual acuity (BCVA) was assessed, and spectral-domain optical coherence tomography was performed at each visit while the percentage of resolution of VMT and the association with various potential adverse events were recorded and analyzed. RESULTS: 66.7% of @entity1 presented VMT release at the end of the follow-up, while 28.6% exhibited @entity937 closure. Severe adverse events, such as enlargement of preexisting @entity937 , were observed in one and four cases, respectively and remained till the end of the follow-up. Moderate adverse events, such as ellipsoid zone disruption and subretinal fluid development, became evident seven days after injection, in four cases. Formation of @entity1103 ( @entity1103 ), not evident at baseline, was noticed in three cases at day 28 after injection. Mild adverse events, like vitreous floaters, photopsias, eye @entity158 , were noticed at day 7 and resolved till the end of the follow-up. CONCLUSIONS: Mild and moderate adverse events occurred mainly during the first week of the follow-up, while severe adverse events, such as the lamellar @entity937 formation and @entity1103 at day 28 post injection were seen.

Complications of intravitreal ocriplasmin for vitreomacular traction and XXXX : a prospective spectral-domain optical coherence tomography study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Participants'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain and foreign body sensation'] @entity1103 :: ('MESH:D008269', 'Disease') :: ['CME', 'cystoid macular edema'] @entity937 :: ('MESH:D012167', 'Disease') :: ['MH and formation of lamellar MH', 'macular hole', 'MH']
@entity937 :: (MESH:D012167,Disease) :: ['macular hole']
